Search
Join Thermo Fisher Scientific at HPLC 2026 in Indianapolis
We’re excited to gather in Indianapolis for HPLC 2026, the premier global conference showcasing the latest advancements in liquid chromatography and related analytical innovations.
Visit us at Booth #201 during exhibit hours to connect with our chromatography experts, exchange ideas, and explore solutions designed to advance your laboratory performance. From cutting-edge instrumentation to innovative workflows and consumables, discover how we’re helping scientists push the boundaries of liquid-phase separation.
HPLC 2026 promises to be an enriching experience for chromatography professionals across academia and industry, offering deep insights into emerging research, evolving technologies, and real-world applications in liquid-phase separation.
Featured experiences
Speakers
Don’t Miss Our Lunch Workshop
Wednesday, June 10
12:30-1:30 p.m.
ASOs, ADCs, and Other Therapeutics: Advanced Characterization with Novel Reversed-Phase Columns and Integrated LC–MS Platform
Biotherapeutics are becoming increasingly structurally diverse, placing greater demands on analytical platforms that can support efficient development and regulatory readiness. Reversed-phase chromatography (RPC) remains a widely adopted and adaptable technique, supporting applications that range from oligonucleotide analysis to detailed protein characterization and post-translational modification assessment.
This seminar explores the integration of a macroporous, monodisperse reversed-phase column with a next-generation bioinert LC system for the analysis of two emerging classes of biotherapeutics. Antisense oligonucleotides were examined under optimized chromatographic conditions, using a design-of-experiments strategy to evaluate how ion-pairing reagents influence both LC separation and downstream MS performance. The platform was further applied to antibody–drug conjugates, combining RPC with Orbitrap mass spectrometry to support multi-level characterization. Intact, sub-unit, and bottom-up analyses enabled drug-to-antibody ratio determination alongside detailed PTM profiling — including glycosylation, oxidation, and deamidation — under native and stress conditions. Collectively, these studies demonstrate a streamlined and adaptable workflow for comprehensive biotherapeutic characterization.
Sara Carillo, Ph.D.
Bioanalytical Research Lead, Characterization and Comparability Laboratory National Institute for Bioprocessing Research and Training (NIBRT), Dublin, Ireland
Sara Carillo completed her Ph.D. in chemical sciences in 2013 at the University of Naples Federico II, where she focused on the structural characterization of polysaccharides and glycoconjugates from Gram-negative bacteria using NMR and mass spectrometry techniques. In 2015, she joined the CCL group at NIBRT, led by Prof. Jonathan Bones. She began her postdoctoral research investigating the effects of extractables and leachables from single-use bioreactors on both the CHO cell N-glycome and the monoclonal antibodies they produce. She currently serves as Bioanalytical Research Lead at NIBRT, where her work centers on developing new mass spectrometry–based analytical approaches to enable deeper and more accessible understanding of biomanufacturing processes and the structural complexity of biopharmaceuticals.
Mauro De Pra, Ph.D.
Product Marketing Manager, LC Columns
Sara Carillo completed her Ph.D. in chemical sciences in 2013 at the University of Naples Federico II, where she focused on the structural characterization of polysaccharides and glycoconjugates from Gram-negative bacteria using NMR and mass spectrometry techniques. In 2015, she joined the CCL group at NIBRT, led by Prof. Jonathan Bones. She began her postdoctoral research investigating the effects of extractables and leachables from single-use bioreactors on both the CHO cell N-glycome and the monoclonal antibodies they produce. She currently serves as Bioanalytical Research Lead at NIBRT, where her work centers on developing new mass spectrometry–based analytical approaches to enable deeper and more accessible understanding of biomanufacturing processes and the structural complexity of biopharmaceuticals.
- Novel direct ion exchange chromatography/mass spectrometry workflow for characterization of phosphorodiamidate morpholino oligomers (PMO)
- Balancing Sensitivity and Throughput: Load-Dependent Flow Rate Optimization in High-Throughput Proteomics
- A novel monodisperse supermacroporous reversed-phase platform for comprehensive nucleic acid analysis across a broad size range
- Secondary-amine-assisted ion-pair reversed-phase LC-HRAM-MS enables intact mass analysis of tRNA
- High-throughout intact mass analysis of synthetic oligonucleotides on atandem LC system using green solvents
- HFIP and amine ior pair free reversed-phase LC-MS platform for automated characterization of therapeutic oligonucleotides
- Cross-laboratory evaluation of Medium- and low-load proteome quantitation using OptiSpray technology on the Orbitrap Astral MS
- A switchable 2D-LC platform in PAT: routine UV monitoring or MS-based characterization of mAb PQAs directly from the bioreactor
- Polymeric, Porous, Monodisperse Particle Development and Application to Reversed Phase Separations of Biological Molecules
- A novel monodisperse supermacroporous reversed-phase platform for comprehensive nucleic acid analysis across a broad size range
- LC–MS analysis of intact and subunit-level monoclonal antibodies enabled by a novel monodisperse supermacroporous reversed-phase platform